Our onco-metabolism approach brings
an enhanced perspective to cancer.
- Company
- Science
- Programs
- Clinical Trials
- Media & Investors
- Financial Information
- Corporate Governance
- Shareholder Services
-
Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Calithera to Participate in Jefferies Virtual Healthcare Conference and SVB Leerink Oncology 1x1 Day
-
Calithera Biosciences Presents New Preclinical Data for CB-668 at Society for Immunotherapy of Cancer (SITC) 2020 Annual Meeting
-
Calithera Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights
-
Calithera Biosciences Announces Expansion of Ongoing Clinical Trial Evaluating Telaglenastat in Combination with palbociclib (IBRANCE®)
Development Pipeline
Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.
Recent News
- Shareholder Services
- Corporate Governance
- Financial Information
- Media & Investors
- Clinical Trials
- Programs
- Science
